Janssen Research & Development *

Statistical Analysis Plan (Final CSR)

A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO136ARA3003 (SIRROUND-T)

Protocol CNTO136ARA3004; Phase 3

CNTO 136 (sirukumab)

*Janssen Research & Development is a global organization that operates through different legal entities in various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen Biologics, BV; Janssen-Cilag International NV; Janssen, Inc; Janssen Sciences Ireland UC; or Janssen Research & Development, LLC. The term “sponsor” is used throughout the protocol to represent these various legal entities; the sponsor is identified on the Contact Information page that accompanies the protocol.

No Statistical Analysis Plan was created for the abbreviated final Clinical Study Report for Protocol CNTO136ARA3004.

Affirmed by:

Yusang Jiang, MA
Study Statistician

Date (Day Mon Year)

Status: Approved
Date: 9 April 2019
Prepared by: Janssen Research & Development, LLC; Janssen Research & Development, a division of Janssen Pharmaceutica NV